Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ALO-02

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Proper management of severe pain represents one of the most challenging clinical dilemmas. Two equally important goals must be… Expand
  • figure 1
  • table 1
  • table 2
2017
2017
Abstract Objective. To evaluate the abuse potential of ALO-02, an abuse-deterrent formulation comprising pellets of extended… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Review
2017
Review
2017
BackgroundThe efficacy of ALO-02, an abuse-deterrent formulation containing extended-release oxycodone and sequestered naltrexone… Expand
  • table 1
  • table 2
  • table 3
2015
2015
Abstract The objective of this multicenter, double-blind, placebo-controlled, randomized withdrawal study was to evaluate the… Expand
2015
2015
ALO‐02 is an abuse‐deterrent formulation consisting of capsules filled with pellets of extended‐release oxycodone surrounding… Expand
2015
2015
Background and ObjectivesALO-02 capsules, intended to deter abuse, contain pellets of extended-release oxycodone hydrochloride… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
2015
2015
ALO‐02 is being developed as an abuse‐deterrent formulation of extended‐release oxycodone hydrochloride with naltrexone… Expand
Review
2014
Review
2014
Abstract Background: For properly selected patients experiencing chronic pain, extended-release opioid formulations may represent… Expand
2014
2014
OBJECTIVE To evaluate the long-term safety of oxycodone-hydrochloride and sequestered naltrexone-hydrochloride (ALO-02… Expand
Review
2014
Review
2014
Background: ALO-02, an opioid formulation intended to deter abuse, comprising capsules filled with pellets of extended-release… Expand
  • table 1
  • table 2
  • figure 2
  • table 3